Letter to the Editor Regarding “Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison” | Publicación